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Clinical ResearchMitraClip Therapy in Surgical
High-Risk Patients
Identiﬁcation of Echocardiographic Variables Affecting
Acute Procedural Outcome
Edith Lubos, MD,* Michael Schlüter, PHD,* Eik Vettorazzi, MSC,y Britta Goldmann, MD,*
Daniel Lubs, MD,* Johannes Schirmer, MD,z Hendrik Treede, MD,z
Hermann Reichenspurner, MD, PHD,z Stefan Blankenberg, MD,* Stephan Baldus, MD,*
Volker Rudolph, MD*
Hamburg, GermanyObjectives The aim of the study was to assess predictors of acute procedural failure in surgical
high-risk patients undergoing MitraClip (Abbott Vascular, Abbott Park, Illinois) therapy.
Background MitraClip implantation is a novel percutaneous option to treat signiﬁcant mitral
regurgitation (MR).
Methods In 300 patients (75  9 years of age, 190 [63%] men), of whom 32 (10.7%) had been
unsuccessfully treated (discharge MR grade of >2þ), baseline clinical and echocardiographic variables
were evaluatedby exact logistic regression and classiﬁcation tree analyses to assess their impact on acute
procedural failure. Acute procedural failure was differentiated into aborted procedure (no MitraClip
implanted; n ¼ 11) and “clip failure” (inadequate MR reduction despite MitraClip implantation; n ¼ 21).
Results Multivariate logistic regression identiﬁed effective regurgitant oriﬁce area (EROA), mitral valve
oriﬁce area (MVOA), andmean transmitral pressure gradient (TMPG) as independent predictors of overall
acute procedural failure. Classiﬁcation tree analysis revealed that an EROA >70.8 mm2 (n ¼ 28) was
associated with a high rate (25%) of clip failures, whereas the combination of an MVOA 3.0 cm2 and a
TMPG4mmHg (n¼ 16) was associated with a high rate (37.5%) of aborted procedures. Failure rates of
10%were observed in all patients with an EROA70.8mm2 and either anMVOA>3.0 cm2 (n¼ 217) or
anMVOA3.0 cm2 in concert with a TMPG3mmHg (n¼ 39). Multinomial logistic regression identiﬁed
an EROA >70.8 mm2 and a TMPG 4 mm Hg as independently predictive of clip failure, but an MVOA
3.0 cm2 and a TMPG 4 mm Hg as independently predictive of procedure abortion.
Conclusions In surgical high-risk patients undergoing MitraClip therapy, a TMPG 4 mm Hg, an EROA
70.8 mm2, and an MVOA 3.0 cm2 carry an increased risk of procedural failure. (J Am Coll Cardiol
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Abbreviations
and Acronyms
CI = conﬁdence interval
DMR = mitral regurgitation of
degenerative/mixed origin
EROA = effective regurgitant
oriﬁce area
FMR = mitral regurgitation of
functional origin
IQR = interquartile range
MR = mitral regurgitation
MVOA = mitral valve oriﬁce
area
OR = odds ratio
TMPG = mean transmitral
pressure gradient
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395Percutaneous mitral valve repair using the MitraClip system
(Abbott Vascular, Abbott Park, Illinois) has become an
accepted therapeutic option in patients with signiﬁcant
mitral regurgitation (MR) deemed at high surgical risk. The
feasibility and safety of the percutaneous approach have been
demonstrated, and its efﬁcacy is currently further tested in
ongoing clinical trials.
Despite reported primary procedure failure rates be-
tween 9% and 23% (1,2), predictors of the acute pro-
cedural outcome have not been assessed to date. To
further improve the technique and possibly allow
appropriate patient selection, identiﬁcation of such pre-
dictors is of paramount importance. We sought to assess
the acute procedural outcomes of 300 consecutive pa-
tients who underwent MitraClip implantation at our
institution and determine variables affecting procedural
failure.
Methods
Patients. Between September 2008 and April 2012, 300
consecutive patients with an MR of grade 3þ (moderate to
severe) or 4þ (severe) were adjudicated as not amenable to
surgery by heart team consensus and underwent MitraClip
therapy at our center. Baseline characteristics of the study
population are given in Table 1. These were elderly patients
with a mean age of 75 years; they had high median logistic
EuroSCORE (European System for Cardiac Operative Risk
Evaluation) of 24% and an increased prevalence of comor-
bidities such as renal failure (55%), atrial ﬁbrillation (65%),
and coronary artery disease (66%). The majority of patients
(68%) had mitral regurgitation of functional etiology (FMR).
Anatomic exclusion criteria of the EVEREST II (Endovas-
cular Valve Edge-to-Edge Repair Study II), (3) such as a left
ventricular end-systolic diameter >55 mm and a mitral valve
oriﬁce area <4.0 cm2, were met by 39% and 57% of the pa-
tients, respectively. All patients had provided written
informed consent before the intervention.
Echocardiography. Echocardiographic measurements were
performed according to American Society of Echocardiog-
raphy and European Association of Echocardiography
guidelines (4,5). In particular, the effective regurgitant
oriﬁce area (EROA) was determined by the proximal iso-
velocity surface area method, and the mitral valve oriﬁce area
(MVOA) was calculated with the pressure half-time method
using the continuous-wave Doppler inﬂow proﬁle; the mean
transmitral pressure gradient (TMPG) was also assessed
from the continuous-wave Doppler inﬂow proﬁle. MR
severity after the intervention was assessed as described
previously (6).
Percutaneous mitral valve repair. Percutaneous mitral valve
repair with the MitraClip system was described in detail
previously (2). Acute procedural success was deﬁned as the
placement of 1 clips resulting in a discharge MR grade of2þ or lower. An aborted procedure was deﬁned as a pro-
cedure in which no clip could be implanted. Intra-
procedurally, a TMPG of no more than 5 mm Hg was
accepted after clip implantation. However, 4 patients with a
higher TMPG already at baseline were accepted for
MitraClip implantation because of the lack of alternative
therapeutic options.
Statistical analysis. Continuous variables are presented as
mean SDor asmedian and interquartile range (IQR), where
appropriate; categorical variables are presented as absolute
numbers and percentages. Comparisons of continuous vari-
ables were performed using the Mann-Whitney U test.
Comparisons of categorical variables were performed by the
Fisher exact test (for 2  2 tables) or chi-square test (for
[n > 2]  2 tables). Exact univariate and multivariate
logistic regression analyses comprising pertinent clinical and
echocardiographic variables, including all EVEREST trial
(EndovascularValveEdge-to-EdgeRepair Study II) exclusion
criteria (3), were used to deter-
mine variables potentially predic-
tive of acute procedural failure.
Regression analyses could not be
performed separately for degener-
ative/mixed origin mitral regurgi-
tation (DMR) and FMR because
of the low number of failures
encountered. Accordingly, these
analyses only included variables
applicable to both MR etiologies.
Variables entered into the logistic
regression analyses are listed in the
Online Appendix. Exact multi-
variate logistic regression analysis
used Firth’s penalized likelihood
approach (7).
To distinguish between pro-cedures that had to be aborted and procedures that did not
result in adequate MR reduction despite clip implantation
(“clip failure”) and to establish the interrelationship of var-
iables affecting either type of procedural failure, all variables
used in the exact logistic regression were also entered into a
classiﬁcation tree analysis. This nonparametric method
constructs a binary tree in which the dataset is split at each
node into 2 subsets using the covariate that has the strongest
association with the procedural outcome. Missing data in
split variables are handled by a “majority vote” for the split
(i.e., for a missing value, it is assumed that it falls in the
larger group of observed values for the corresponding split).
The ﬁnal result is a tree that depicts the best variables to split
the data and provides information about relevant variables
for each class of objects (i.e., success, aborted procedure, and
clip failure). Bonferroni corrections for multiple testing were
used when “growing” the tree. In a ﬁnal step, an exact
multinomial logistic regression, with cutoffs determined
Table 1. Baseline Patient Characteristics
All Patients
(n ¼ 300)
Success
(n ¼ 268)
Failure
(n ¼ 32) p Value*
Age, yrs 75  9 75  8 73  13 0.7768
Age >75 yrs 150 (50) 132 (49) 18 (56) 0.4626
Men 190 (63) 171 (64) 19 (59) 0.6987
Logistic EuroSCORE, % 24 (13–41) 24 (13–42) 24 (12–32) 0.5410
Hypertension 207/299 (69) 189/267 (71) 18 (56) 0.1061
Hypercholesterolemia 159 (53) 145 (54) 14 (44) 0.3490
Diabetes 100 (33) 91 (34) 9 (28) 0.5582
COPD 61 (20) 54 (20) 7 (22) 0.8175
Renal failure 164 (55) 150 (56) 14 (44) 0.1953
Atrial ﬁbrillation 195 (65) 178 (66) 17 (53) 0.1695
CAD 199 (66) 182 (68) 17 (53) 0.1135
Cardiomyopathy 0.0811
Dilated 76/296 (26) 71/264 (27) 5/32 (16)
Ischemic 138/296 (47) 125/264 (47) 13/32 (41)
None 82/296 (28) 68/264 (26) 14/32 (44)
NYHA functional class 0.6476
II 11 (4) 9 (3) 2 (6)
III 193 (65) 174 (65) 19 (59)
IV 95 (32) 84 (32) 11 (34)
NT-proBNP, pg/ml 3,561 (1,795–8,069)
(n ¼ 258)
3,561 (1,865–8,177)
(n ¼ 232)
2,969 (1,493–7,288)
(n ¼ 26)
0.4729
MR severity grade 0.0022
3þ (moderate to severe) 164 (55) 155 (58) 9 (28)
4þ (severe) 136 (45) 113 (42) 23 (72)
Functional MR 205 (68) 189 (71) 16 (50) 0.0259
LVEF 43  16
(n ¼ 289)
42  15
(n ¼ 257)
47  17 0.1275
LVEF <25% 45/289 (16) 41/257 (16) 4/32 (13) 0.7975
LVEDD, mm 65  11
(n ¼ 290)
65  11
(n ¼ 258)
66  13 0.9920
LVESD, mm 52  13
(n ¼ 288)
52  13
(n ¼ 256)
50  16 0.2140
LVESD >55 mm 112/288 (39) 102/256 (40) 10 (31) 0.4426
EROA, mm2 41 (33–58)
(n ¼ 259)
41 (32–55)
(n ¼ 234)
56 (40–90)
(n ¼ 25)
0.0050
MVOA, cm2 3.9  1.1
(n ¼ 270)
3.9  1.1
(n ¼ 239)
3.5  1.0
(n ¼ 31)
0.0370
MVOA <4.0 cm2 155/270 (57) 134/239 (56) 21/31 (68) 0.2502
TMPG, mm Hg 2.5  1.8
(n ¼ 270)
2.4  1.8
(n ¼ 240)
3.6  1.7
(n ¼ 30)
0.0001
Values are median  SD, n (%), or median (interquartile range). *Success vs. failure.
CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; EROA ¼ effective regurgitant oriﬁce area; EuroSCORE ¼
European System for Cardiac Operative Risk Evaluation; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection fraction;
LVESD ¼ left ventricular end-systolic diameter; MR ¼ mitral regurgitation; MVOA ¼ mitral valve oriﬁce area; NT-proBNP ¼ N-terminal pro–B-type
natriuretic peptide; NYHA ¼ New York Heart Association; TMPG ¼ mean transmitral pressure gradient.
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396from the classiﬁcation tree analysis, was performed. Com-
parisons between terciles for assessment of the procedural
learning curve were calculated by chi-square test for trend in
proportions. A 2-sided p value <0.05 was considered statis-
tically signiﬁcant. R software, version 2.15.2 (R Foundation
for Statistical Computing, Vienna, Austria), was used for
statistical analyses. For logistic regressions, the exact methodsimplemented in the R packages logistf and pmlr were used;
classiﬁcation tree analysis used the R party package (8).
Results
Procedural outcomes. Acute procedural success was ach-
ieved in 268 patients (89.3%), with a single clip implanted in
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397177 (66%) and multiple clips implanted in 91 patients.
Median device time (i.e., time from transseptal puncture to
withdrawal of the clip delivery system from the left atrium)
amounted to 63 min (IQR: 41 to 101 min) in successfully-
treated patients. Procedural failure in 32 patients was due
to failure to implant a clip (i.e., aborted procedures) in
11 patients and failure to reduce MR severity to grade
2þ despite clip implantation (clip failure) in the other
21 patients (1 clip in 10, 2 clips in 11 patients). Median
device time in these 32 patients was 75 min (IQR: 61 to
131 min) (p ¼ 0.0142 vs. successfully-treated patients).
Online Figure 1 shows the impact of MitraClip implanta-
tion on MR severity.
Baseline characteristics of patients according to procedural
outcome (success vs. overall failure) are given in Table 1.
Compared with successfully-treated patients, patients in
whom MitraClip therapy failed more often had DMR
(Fig. 1), and the severity of MR was more often grade 4þ.
Moreover, they had a signiﬁcantly larger median EROA
(56 mm2 vs. 41 mm2), a signiﬁcantly smaller MVOA
(3.5 cm2 vs. 3.9 cm2), and a signiﬁcantly higher TMPG
(3.6 mm Hg vs. 2.4 mm Hg). Pertinent baseline charac-
teristics of the 32 patients with procedural failure are given
in Table 2.
Baseline patient characteristics and procedural outcomes
according to MR etiology. Because DMR (n ¼ 95) and
FMR (n ¼ 205) represent highly distinct morphological and
clinical entities, it is prudent to assess potential differences
between the etiologies in baseline variables that might affectFigure 1. Procedural Outcome According to the Etiology of
Mitral Regurgitation
Stacked columns show success rates in green and failure rates in red for
95 patients with degenerative/mixed etiology of mitral regurgitation (DMR)
and 205 patients with functional etiology of mitral regurgitation (FMR).
Respective numbers of patients are also given. In patients with DMR, 16 failed
procedures amount to a failure rate of 16.8%, whereas 16 failed procedures in
FMR patients amount to a failure rate of 7.8%. The difference in failure rates is
statistically signiﬁcant (p ¼ 0.0259).procedural outcome. DMR patients differed from FMR
patients in that they had a higher prevalence at baseline of
grade 4þMR (n ¼ 55 [58%] vs. n ¼ 81 [40%]; p ¼ 0.0040)
and, accordingly, a larger median EROA (52 mm2 [IQR: 35
to 71 mm2] vs. 39 mm2 [IQR: 32 to 49 mm2]; p < 0.0001).
Furthermore, TMPG was signiﬁcantly increased in DMR
patients (3.4  2.3 mm Hg vs. 2.1  1.3 mm Hg;
p < 0.0001). The difference in MVOA (DMR: 3.9 
1.1 cm2 vs. FMR: 3.7  0.9 cm2) did not reach statistical
signiﬁcance (p ¼ 0.085).
Procedural failures were encountered signiﬁcantly more
often in DMR than FMR patients (Fig. 1). No difference
between FMR and DMR was encountered with regard to
the distribution of the type of procedural failure (aborted
procedure and clip failure) (DMR, 5 [31%] and 11 [69%] vs.
FMR, 6 [38%] and 10 [62%]; p ¼ 0.913).
Predictors of overall procedural failure. When all procedural
failures (n ¼ 32) were compared with the 268 successfully-
treated patients, MR etiology, EROA, TMPG, and
MVOA were identiﬁed as univariate predictors of proce-
dural failure by exact binary logistic regression analysis
(Table 3). On exact multivariate logistic regression, only
EROA and TMPG remained independently predictive of
overall procedural failure, with the odds of failure increasing
by a factor of 1.21 (95% conﬁdence interval [CI]: 1.09 to
1.39, i.e., by 21% [95% CI: 9% to 39%] per 10-mm2 in-
crease in EROA) and a factor of 1.26 (95% CI: 1.03 to 1.54,
i.e., by 26% [95% CI: 3% to 54%] per 1-mm Hg increase in
TMPG) (Table 3).
Predictors of differential procedural outcome. When EROA,
MVOA, and TMPG were entered into a classiﬁcation tree
analysis, the interrelationship between these variables with
respect to their impact on abortion of the procedure or clip
failure on the one hand and procedural success on the other
was revealed in 4 different outcome groups (Fig. 2). The
ﬁrst split at the root of the tree occurred at an EROA of
70.8 mm2, because the highest rate of clip failure (7 patients,
25%) was encountered in the 28 patients with an EROA
>70.8 mm2. Of the 7 clip failure patients, 5 (71%) had
DMR, with a ﬂail leaﬂet being responsible for the high
EROA in 4 of the 5 patients, and 2 patients had FMR, with
a complete loss of leaﬂet coaptation present in 1 of them. A
similarly high rate of clip failure was not observed in any of
the subgroups of patients with an EROA 70.8 mm2.
The next split at an MVOA of 3.0 cm2 identiﬁed the
217 patients with an EROA 70.8 mm2 and an MVOA
>3.0 cm2 in whom the highest success rate (204 of 217,
94.0%) of all patient subgroups was seen. TMPG had no
impact on procedural outcome in these patients.
The overall success rate in the 55 patients with an EROA
70.8 mm2 but an MVOA 3.0 cm2 was 80% (n ¼ 44).
However, a TMPG 4 mm Hg in concert with an MVOA
3.0 cm2, present in 16 patients, yielded the lowest success
rate (56.3%, 9 patients) of all subgroups and the highest rate
Table 2. Pertinent Baseline Variables in Patients With Procedural Failures
Patient # Sex
Age,
yrs Etiology
MR
Grade
Clips
Implanted
MVOA,
cm2
TMPG,
mm Hg
EROA,
mm2
9 F 71.2 FMR 4þ 0 4.6 2 44
28 M 80.8 DMR 4þ 2 3.4 6 38
31 M 47.0 FMR 4þ 0 4.5 4 119
44 M 78.3 DMR 4þ 3 4.1 5 157
63 M 69.0 FMR 4þ 3 3.2 2 45
77 F 61.5 DMR 3þ 0 2.2 5 34
97 M 81.6 DMR 4þ 0 2.4 8 62
105 F 81.6 DMR 4þ 2 4.4 7 74
110 F 75.7 FMR 4þ 2 5.2 2 d
132 F 56.3 DMR 3þ 0 2.3 6 d
136 M 75.2 DMR 4þ 0 2.8 4 d
163 F 88.6 DMR 4þ 1 2.2 2 56
172 M 82.9 FMR 3þ 1 2.5 1 20
175 M 80.9 FMR 4þ 1 4.0 4 90
181 M 80.2 FMR 3þ 0 3.3 1 d
188 M 53.5 FMR 4þ 1 3.9 3 51
195 F 84.5 DMR 4þ 1 3.1 3 56
204 M 80.8 FMR 3þ 2 4.9 3 31
214 F 91.3 DMR 4þ 1 d d d
215 M 72.7 FMR 3þ 2 2.2 1 92
219 F 48.9 DMR 3þ 0 4.7 4 61
221 M 61.6 DMR 3þ 1 2.8 4 33
224 M 67.4 FMR 4þ 0 3.0 4 40
225 M 81.1 DMR 4þ 3 3.3 4 94
231 F 88.6 DMR 4þ 2 3.5 2 113
233 F 77.3 FMR 4þ 1 3.1 d d
240 M 44.9 FMR 4þ 0 2.6 4 48
244 M 74.9 DMR 4þ 2 5.8 4 227
251 M 72.5 FMR 4þ 2 4.1 2 43
264 F 78.8 FMR 3þ 0 2.1 2 30
273 M 69.6 FMR 4þ 1 3.7 4 71
290 F 90.0 DMR 4þ 1 3.9 4 d
DMR ¼ degenerative/mixed etiology of mitral regurgitation; FMR ¼ functional etiology of mitral regurgitation; other abbreviations as in Table 1.
Table 3. Logistic Regression Analyses of All Procedural Failures
(n ¼ 32) Versus Successful Therapy (n ¼ 268)
Odds Ratio (95% CI) p Value
Exact univariate logistic regression analysis
EROA (per 10-mm2 increase) 1.25 (1.10–1.42) <0.001
TMPG 1.31 (1.11–1.55) 0.002
MVOA 0.66 (0.44–0.97) 0.033
FMR vs. DMR 0.42 (0.20–0.88) 0.021
Exact multivariate logistic regression analysis
EROA (per 10-mm2 increase) 1.21 (1.06–1.39) 0.005
TMPG 1.26 (1.03–1.54) 0.029
MVOA 0.68 (0.41–1.06) 0.092
FMR vs. DMR 0.78 (0.32–2.03) 0.608
CI ¼ conﬁdence interval; other abbreviations as in Tables 1 and 2.
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398of aborted procedures (37.5%, n ¼ 6). DMR was present in
4 of the 6 patients; the causes of MR were leaﬂet prolapse in
3 patients and pre-existing mitral stenosis in an annuloplasty
ring in 1 patient. When TMPG was 3 mm Hg, a success
rate of 89.7% (35 of 39 patients) was encountered despite
the presence of an MVOA 3.0 cm2.
Exact multinomial logistic regression analysis (Table 4,
Fig. 3) validated the classiﬁcation tree analysis by showing
that an EROA >70.8 mm2 (odds ratio [OR]: 5.54; 95% CI:
1.80 to 16.3) and a TMPG 4 mm Hg (OR: 3.08; 95% CI:
1.04 to 8.75) are independently predictive of clip failure,
whereas an MVOA 3.0 cm2 (OR: 0.19; 95% CI: 0.04 to
0.82) and a TMPG 4 mm Hg (OR: 11.0; 95% CI: 2.7 to
61.8) are independently predictive of an aborted procedure.
Learning curve. Because no formal criteria for patient
selection are in effect at our institution, a potential learning
curve must be appreciated when interpreting our results.
Figure 2. Classiﬁcation Tree
Hierarchical decision tree assigning 300 patients to outcome groups based on cutoff values of echocardiographic variables effective regurgitant oriﬁce area (EROA),
mitral valve oriﬁce area (MVOA), and mean transmitral pressure gradient (TMPG). Outcome is differentiated into success (S, green), procedure abortion (A, red), and
clip failure (F, pink). EROA <70.8 mm2 identiﬁes 28 patients with the highest incidence of clip failure; an EROA 70.8 mm2 and an MVOA <3.0 cm2 identiﬁes 217
patients with the highest success rate, yet an MVOA 3.0 cm2 in conjunction with a TMPG 4 mm Hg identiﬁes 16 patients with the highest incidence of procedure
abortion; despite an MVOA 3.0 cm2, a TMPG 3 mm Hg identiﬁes another 39 patients with a high success rate.
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399There was a nonsigniﬁcant trend (p ¼ 0.067) toward an
increase of the procedural failure rate throughout our expe-
rience, with an overall failure rate of 7% in the ﬁrst 100
patients, 10% in the second tercile, and 15% in the third
tercile (Online Fig. 2). Interestingly, the prevalence of pa-
tients with an MVOA <3.0 cm2 also increased from the
ﬁrst to the last tercile (17% in the ﬁrst, 22.5% and 28.7%
in the second and third terciles, respectively). None of the
other variables identiﬁed as predictors of procedural failure
revealed such a trend (Online Table 2).
Discussion
In this single-center study of 300 elderly high-risk patients
with predominantly FMR, most of whom would not have
been enrolled in the EVEREST II trial, a low overall
procedural failure rate of 10.7% was encountered (9). Pro-
cedural failure was due to either failure to implant a
MitraClip (aborted procedure in 3.7% of patients) or failureto reduce MR severity to grade 2þ despite clip implan-
tation (clip failure, 7.0%). The main ﬁnding of this study
was that variables reﬂecting either the degree of mitral
regurgitation (EROA) or the degree of mitral stenosis
(MVOA and TMPG) emerged as predictors of overall
procedural failure. For clip failure, an EROA 70.8 mm2
and a TMPG 4 mm Hg were independently predictive,
whereas TMPG 4 mm Hg and MVOA 3.0 cm2 were
independently predictive of an aborted procedure.
Effective regurgitant oriﬁce area. Interestingly, EROA was
identiﬁed as the most signiﬁcant predictor of overall acute
procedural outcome; as shown in the classiﬁcation tree
analysis, an EROA >70.8 mm2 revealed a subgroup of
patients at particularly high risk of clip failure (i.e., for
inadequate MR reduction despite clip implantation inde-
pendently of MR etiology). Such a high EROA is commonly
the manifestation of severe pathology of the mitral valve.
In fact, of the 7 patients with clip failure and an EROA
>70.8 mm2, 5 patients with DMR had a ﬂail mitral leaﬂet,
Table 4. Exact Multinomial Logistic Regression (Aborted Procedure
[n ¼ 11] Versus Clip Failure [n ¼ 21] Versus Successful Therapy
[n ¼ 268]) of Variables Dichotomized According to Classiﬁcation Tree
Odds Ratio (95% CI) p Value
Clip failure vs. successful therapy
EROA >70.8 mm2 5.54 (1.80–16.3) <0.001
MVOA >3.0 cm2 0.74 (0.25–2.58) 0.609
TMPG 4 mm Hg 3.08 (1.04–8.75) 0.042
Aborted procedure vs. successful therapy
EROA >70.8 mm2 1.92 (0.18–11.3) 0.535
MVOA >3.0 cm2 0.19 (0.04–0.82) 0.027
TMPG 4 mm Hg 11.0 (2.67–61.8)` <0.001
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
Lubos et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 4 , 2 0 1 4
Predictors of Acute MitraClip Failure A P R I L 2 0 1 4 : 3 9 4 – 4 0 2
4001 patient with FMR had a complete loss of leaﬂet coaptation,
and 1 other patient had an excellent intraprocedural result
after implantation of 1 clip even after norepinephrine chal-
lenge, but showed severe MR on discharge without evidence
of clip detachment.
MVOA and TMPG. Patients with an EROA 70.8 mm2 and
an MVOA >3.0 cm2 exhibited an excellent procedural
success rate of 94.0%. It is therefore reasonable to assume
that the simultaneous presence of these 2 features provides
strong evidence in favor of MitraClip therapy. In contrast,
in patients with an MVOA <3.0 cm2, the success rate
decreased to 80% and further to only 56% if the reduced
MVOA was combined with a TMPG 4 mm Hg. Not
surprisingly, in 4 of 6 patients in the latter subgroup, the
procedure was aborted because clip implantation resulted in
an unacceptably high TMPG. In the other 2 patients of this
group, the procedure was aborted because of a short lengthFigure 3. Exact Multinomial Regression Analysis
Forest plot showing odds ratios (squares) with 95% conﬁdence intervals (horizonta
siﬁcation tree-derived cutoff values of EROA, MVOA, and TMPG. Horizontal lines not c
Thus, an EROA <70.8 mm2 increases the odds of clip failure by a factor of 5.54, an M
a TMPG 4 mm Hg increases the odds of both clip failure and procedure abortion.of the posterior mitral leaﬂet in 1 patient and the inability to
advance the guide catheter in the other.
MR etiology and morphological aspects of the mitral
valve. In our population, procedural failures occurred more
often in DMR than in FMR, which, despite the low number
of events, is in line with the opinion of most interventionists
that DMR poses a relatively greater challenge to MitraClip
therapy. Nevertheless, according to our analyses, MR etiol-
ogy was not identiﬁed as an independent predictor of pro-
cedural failure, whereas the predictive value of EROA,
MVOA, and TMPG was independent of MR etiology.
Thus, although, for example, an EROA >70.8 mm2 is likely
more prevalent in DMR, and indeed was in our population,
the likelihood of failure is equally high in FMR and DMR
once an EROA >70.8 mm2 is encountered.
Our data thus do not indicate that the higher risk of
procedural failure in DMR patients should be taken as an
argument against MitraClip therapy in these patients.
Instead, our data advocate that variables predictive of pro-
cedural failure, such as those presented in this study, should
be assessed regardless of MR etiology to possibly reduce
procedural failure rates further and obtain durable MR
reduction.
Pronounced elevation of EROA as well as increased
TMPG and decreased MVOA must necessarily be a result
of morphological or geometric alterations of the mitral
valve apparatus (10–12). The complexity of the patho-
morphology of MR poses several challenges when trying to
formally assess which morphological aspects of the mitral
valve predict procedural failure: some variables commonly
thought to affect procedural outcome are speciﬁc to MR
etiology (e.g., coaptation depth in FMR, location of ﬂaill lines) for procedure abortion (blue) and clip failure (red) according to clas-
rossing the line of identity indicate the statistical signiﬁcance of the odds ratio.
VOA <3.0 cm2 reduces the odds of procedure abortion by a factor of 0.19, and
Abbreviations as in Figure 2.
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401leaﬂet in DMR) and may require further subclassiﬁcation
(e.g., ﬂail gap). However, the low number of procedural
failures in our study deﬁed analyses according to MR eti-
ology. Furthermore, some morphological variables may
interact with each other (e.g., leaﬂet calciﬁcation with short
leaﬂet length), which again would necessitate large numbers
of patients with that feature to obtain robust regression
analysis results. Finally, predictor variable analyses might
be obscured by factors that are difﬁcult to account for,
such as the unexpected difﬁculty to advance the guide
catheter through the inferior vena cava because of previous
abdominal trauma.
Practical implications. Accordingly, EROA, MVOA, and
TMPG emerge as clinically useful variables when evaluating
patients for MitraClip implantation regardless of the etiol-
ogy of MR. These variables are routinely assessed in most
echocardiographic facilities, and their assessment is well
deﬁned by current echocardiographic guidelines (5,13).
They could be applied in 3 ways: 1) the combination of an
EROA 70.8 mm2 and an MVOA >3.0 cm2 strongly
supports the technical feasibility of MitraClip implantation;
2) in contrast, pathological values of the these variables
mandate critical morphological evaluation of the suitabilityFigure 4. Decision Tree for Guidance in Patient Selection
In patients with valvular morphology suitable for MitraClip therapy, patient selection
tree analysis. In patients with an EROA 70.8 mm2 and an MVOA >3.0 cm2, or an MVO
presence of both an MVOA 3.0 cm2 and a TMPG 4 mm Hg, clip implantation may
with an excessive EROA >70.8 mm2, further evaluation as to the suitability of MitraClip
other abbreviations as in Figure 2.for MitraClip therapy, and every effort should be taken to
identify such a pathology; and 3) if an untoward morphology
for MitraClip implantation is encountered, these parameters
might give additional guidance in separating morphologies
still amenable for MitraClip from those with a high risk of
procedural failure.
Figure 4 illustrates a potential decision tree for guidance
in patient selection. Once commonly accepted contraindi-
cations (14) are ruled out, selection could be guided by the
echocardiographic variables evaluated in the present study.
In cases of an EROA 70.8 mm2 and an MVOA
>3.0 cm2, a high rate of success can be expected; however,
in cases of an MVOA 3.0 cm2 and a TMPG 4 mm Hg,
MitraClip therapy should only be performed exceptionally.
In patients with an EROA >70.8 mm2, further evaluation
is required. Issues that appear to be of importance in this
context are annular diameter (particularly bicommissural)
and annular calciﬁcation, to evaluate whether implantation
of multiple clips is feasible, and assessment of achievability
of leaﬂet grasping (e.g., absent coaptation in FMR or late
ﬂail gap in DMR). However, the signiﬁcance of these pa-
rameters in this setting will have to be evaluated in future
studies.may be guided by the echocardiographic variables assessed in the classiﬁcation
A 3.0 cm2 but a TMPG 3 mm Hg, a high success rate can be expected. In the
not be possible and other therapeutic options should be considered. In patients
therapy is required (see the text for more details). PML ¼ posterior mitral leaﬂet;
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402Study limitations. Despite the relatively high total number
of patients who underwent MitraClip therapy in our study,
it must be emphasized that the number of patients reaching
the endpoint of procedural failure is low. Therefore, analyses
separated by etiology could not be performed and variables
speciﬁc to either etiology were not assessed. For the same
reason, it cannot be ruled out that procedural failure of
MitraClip therapy might be inﬂuenced by additional pa-
rameters, which, although included in our analyses, might
require larger numbers of events to be identiﬁed as relevant
for procedural outcome. Thus, even though it cannot be
claimed that our analyses are comprehensive, they provide a
solid base for the assumption that EROA, TMPG, and
MVOA are important predictors for procedural failure in
MitraClip therapy. Additionally, it must be mentioned that
echocardiographic variables were not assessed by an inde-
pendent core laboratory.
Furthermore, our data reﬂect the experience of a single
center, and thus care must be taken when extrapolating
these results to other centers. Nevertheless, it is reasonable
to assume that the predictors identiﬁed herein are of value
for patient selection as their assessment has been well
deﬁned over the years, and it is reasonable to assume that
the identiﬁed parameters reﬂect true technical limitations
of the procedure, although cutoff values may shift (e.g.,
depending on the experience with the procedure). More-
over, a learning curve with regard to all procedural aspects,
including patient selection, interventional approach, and
procedural outcomes, must be appreciated. Indeed, proce-
dural failure rates showed a nonsigniﬁcant trend toward an
increase throughout the period of observation, along with
a signiﬁcant increase in the prevalence of patients with
an MVOA <3.0 cm2, which might point toward a more
liberal patient selection with growing experience. In this
context, it is important to point out that no formal exclu-
sion criteria (e.g., EVEREST criteria) were pre-deﬁned for
patient selection. On the one hand, this might have resulted
in variation of these criteria throughout the observation
period, but, on the other hand, it allowed us to demonstrate
that MitraClip therapy is feasible with a high procedural
success rate in patients not fulﬁlling the anatomic exclusion
criteria deﬁned in EVEREST.Conclusions
Our study shows that, regardless of MR etiology, EROA,
MVOA, and TMPG are independently predictive of acute
procedural failure in surgical high-risk patients undergoing
MitraClip implantation. These variables thus evolve asreadily assessable, well-validated variables to guide patient
selection for MitraClip therapy.
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